Nobel laureate Shimon Sakaguchi reflects on the role of regulatory T cells in peripheral immune tolerance and how the cells ...

In a breakthrough cancer therapy development, scientists at MIT and Harvard Medical School created a new way of designing ...

GlyTR1的设计中蕴含着一个更为深刻的智慧。它所靶向的β1,6-分支化N-聚糖，本身就是一种重要的免疫抑制性分子。在T细胞和癌细胞表面，这种糖链会与一种叫做半乳糖凝集素 (galectins) 的蛋白相互作用，形成一个巨大的“分子晶格” ...

UMass Amherst researchers have developed a groundbreaking nanoparticle-based cancer vaccine that prevented melanoma, pancreatic, and triple-negative breast cancers in mice—with up to 88% remaining ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Early research has identified several antigens that could ...

Providence Cancer Institute’s executive medical director, Bryan Bell, M.D., D.D.S, FACS, FRCS(Ed), recently discussed recent ...

Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss—No Target Is Out of the Realm of Possibility Modified, autologous T-cell immunotherapies have been ...

By targeting a newly uncovered weakness in prostate cancer cells, this could offer an improved treatment for the disease.

MIT and Harvard scientists have created engineered CAR-NK cells that can hide from the immune system and more effectively ...

Cancer cells transfer mitochondria through nanotubes to healthy neighboring cells, turning them into tumor-supporting accomplices, a new study shows.